Breast Clinical Trial
Official title:
A Pharmacodynamic Study of the P-glycoprotein (Pgp) Antagonist, CBT-1(Registered Trademark), Evaluating Pgp Inhibition in Tumors and Normal Tissues
Background:
- Some cancer cells have a large amount of a protein called P-glycoprotein, which can
pump certain chemotherapy drugs out of their cells. This pump may be part of the reason
why it is difficult to shrink some cancers with chemotherapy.
- In laboratory experiments, the drug CBT-1(Registered Trademark) blocked the
P-glycoprotein pump, resulting in accumulation of higher amounts of chemotherapy inside
the cancer cells, making the chemotherapy more effective.
- Paclitaxel is a cancer drug that has caused tumors to shrink in many types of cancers,
including lung, ovarian, breast, renal, cervical and others.
Objectives:
- To determine whether CBT-1(Registered Trademark) can block the P-glycoprotein pump on
cancer cells and whether it inhibits the action of the pump found in normal blood cells
and liver tissue.
- To evaluate the effectiveness of combination therapy using CBT-1(Registered Trademark)
and paclitaxel in treating solid tumors and to determine whether the two drugs together
are more effective than paclitaxel alone.
Eligibility:
-Patients over 18 years of age who have a solid tumor that cannot be treated successfully
with standard treatments.
Design:
-Patients receive CBT-1(Registered Trademark) and paclitaxel in 21-day cycles. Treatment
continues for two cycles after all the cancer is gone, or until it is decided to surgically
remove some or all of the remaining cancer, or until the cancer has grown to the point where
it defined as progressive disease.
For each cycle, patients take CBT-1(Registered Trademark) by mouth in three divided doses
daily for 7 days. On day 6, paclitaxel is given through a vein over 3 hours.
Blood tests are done before starting CBT-1(Registered Trademark) and repeated periodically
throughout treatment.
Imaging studies computed tomography or magnetic resonance imaging (CT or MRI) are done every
two cycles. In addition, for the first cycle only, patients undergo imaging of tumors and
normal tissue with a 99mTc-sestamibi radionuclide scan before and after administration of
CBT-1(Registered Trademark). This scan helps show how well the P-glycoprotein pump is being
blocked by the treatment.
Status | Completed |
Enrollment | 12 |
Est. completion date | June 2009 |
Est. primary completion date | June 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
- INCLUSION CRITERIA: Patients must fulfill all of the following criteria to be eligible for study admission: 1. Age greater than 18 years. 2. Histologic or cytologic confirmation at National Cancer Institute (NCI) Laboratory of Pathology, of recurrent or refractory, or advanced metastatic cancer of the gastrointestinal tract, breast, Taxol (Trademark) naive breast cancer, small cell lung, ovarian, prostate, head and neck, multiple myeloma, non-small cell lung cancer, Taxol (Trademark) naive non-small cell lung cancer. 3. Performance status of Eastern Cooperative Oncology Group (ECOG) 0-2. 4. Life expectancy of 3 months or greater. 5. Patient must have adequate hematologic, renal, hepatic, and metabolic functions as defined: platelet count greater than 100,000 /mL, absolute granulocyte count (AGC) greater than 1500/mL, serum creatinine less than 2.0 mg/dl (or if greater than 2.0, a measured 24 hour creatinine clearance greater than 50 mL/min), serum glutamic oxaloacetic transaminase (SGOT) 4 times institutional upper limit of normal, bilirubin 2.0 mg/dl, prothrombin time (PT) less than 1.5 times institutional upper limit of normal, partial thromboplastin time (PTT) less than 1.5 times institutional upper limit of normal, calcium less than 5.3mEq/L, albumin greater than 2.0 g/dl. 6. Electrocardiogram (EKG) showing, at most, minor abnormalities that in the judgment of the protocol chairman would not compromise the patient's ability to tolerate therapy. 7. Patients must be greater than 4 weeks from prior radiation or chemotherapy; greater than 2 weeks from hormonal or immunotherapy; greater than 4 weeks from prior experimental therapy; greater than 6 weeks from mitomycin; and greater than 8 weeks from prior UCN01 treatment. Patients receiving dexamethasone as a pretreatment for anaphylactic reactions to Taxol (Trademark) or the cremophor vehicle will not be excluded from this study. 8. No serious intercurrent medical illness or serious infection that requires parenteral antibiotics. 9. Measurable disease by radiographic means or physical examination. 10. Willingness to sign a written informed consent. 11. Patients must agree to an effective method of contraception for the study (abstinence, hormonal or barrier method of birth control, or condom) for the study and 30 days after completion of protocol. EXCLUSION CRITERIA: The following patient populations are not eligible for study: 1. Women of childbearing potential and potentially fertile men will be excluded unless using an effective contraception (ie. a barrier intrauterine device (IUD), birth control pill, or condom), during the treatment. Women who are pregnant or nursing will also be excluded. 2. Patients with significant intercurrent disease. 3. Human Immunodeficiencey virus (HIV) seropositive patients. Note: There may be an impact of CBT-1 on the pharmacokinetics of the drugs used in the therapy of HIV. 4. Ongoing serious infections that require parenteral antibiotics. 5. Patients with significant central nervous system (CNS) disease, including a history of seizures within the last 3 months or psychiatric history which would impair the ability to give informed consent or prevent compliance with protocol requirements. 6. Patients must not be eligible for surgery, or radiotherapy that is of known benefit to them, in terms of extension of survival. Patients with tumors sensitive to potentially curative chemotherapy must have failed such chemotherapy. Patients who have received radiation therapy may participate in this study one week after the conclusion of radiation therapy provided that the lesion being irradiated is not one that is being used to assess the efficacy of CBT-1 plus Taxol. 7. History of significant coronary artery disease, cardiac arrhythmias requiring treatment, or history of other cardiac disease that in the judgment of the investigators, would compromise the patient's ability to tolerate the therapy. 8. Patients with active bleeding due to peptic ulcer disease. 9. History of anaphylactic reactions to paclitaxel or cremophor despite adequate premedication. 10. Clinically significant bleeding disorders. 11. Patients with solid organ allografts. 12. Patients on daily gastric acid secretion inhibitors. |
Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent Increase in Sestamibi Retention in the Liver as a Measure of P-glycoprotein Inhibition | An area under the concentration curve (AUC) was calculated for 99mTc counts over the liver, lungs, and heart. An equation was applied to determine the increase in sestamibi in the liver: [(AUCpost - AUC baseline)/(AUC baseline)] x 100. | sestamibi scanning was performed on day 0 and day 6, allowing scans to be performed pre and post CBT-1 administration | No |
Primary | Number of Participants With Adverse Events | Here are the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. | 18 months | Yes |
Secondary | Percent Inhibition of Rhodamine Efflux From CD56+Cells Post Treatment | Rhodamine 123 was added to whole blood obtained before and after CBT-1. The blood was incubated, layered on lymphocyte separation medium and centrifuged. Peripheral blood mononuclear cells(PBMCs)were isolated, washed and incubated in rhodamine-free medium with or without valspodar. Cells were washed and incubated in phycoerythrin-labeled anti-CD56 antibody or negative control antibody. Rhodamine 123 fluorescence was assessed in CD56+cells with or without valspodar and a 60 min efflux period,continuing the cells without or with valspodar to generate Efflux and PSC/Efflux histograms. | Rhodamine efflux was performed on blood drawn prior to CBT-1 ingestion and after 6 days of dosing. | No |
Secondary | Number of Participants Who Had an Overall Response | Response is determined by the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Complete response (CR)-disappearance of all target lesions, Partial response (PR)-at least a 30% decrease in the sum of the longest diameter(LD)of target lesions, stable disease (SD) - neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. See the Protocol Link module for further details about the RECIST Criteria. |
Baseline to progression | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04333706 -
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05016310 -
A Study of High-Dose Vit D Versus Standard of Care Vit D Supplementation
|
N/A | |
Completed |
NCT00026689 -
Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols
|
||
Active, not recruiting |
NCT04715802 -
Options on the Breast Reconstruction Timing and Method After Removal of Polyacrylamide Hydrogel
|
||
Recruiting |
NCT05720039 -
Robotic vs. Open NSM for Early Stage Breast Cancer
|
N/A | |
Recruiting |
NCT06157879 -
Measuring Electrical Properties of Breast Tissues
|
N/A | |
Completed |
NCT00277069 -
Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06083415 -
Early Breast Growth in Girls Aged 6 to 8 Years in the Current Environmental Context
|
N/A | |
Active, not recruiting |
NCT02734004 -
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
|
Phase 1/Phase 2 | |
Recruiting |
NCT03047122 -
Detection of Breast Lesions by Automatic Breast US
|
N/A | |
Withdrawn |
NCT01114984 -
Post-Breast Procedure Pain Syndrome Study
|
N/A | |
Recruiting |
NCT05290402 -
Development of an Application-Based Digital Navigator for Perioperative Breast Surgery Patients
|
||
Active, not recruiting |
NCT01078662 -
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
|
Phase 2 | |
Not yet recruiting |
NCT05663801 -
Magnesium Sulphate Versus Ketamine as an Adjuvant to Bupivacaine in Pectoral Nerve Block During Mastectomy
|
Phase 2 | |
Terminated |
NCT00277004 -
Physiological Biomarkers of Cancer Treatment Related Fatigue in Women With Breast Cancer.
|
||
Completed |
NCT04524728 -
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
|
||
Withdrawn |
NCT00845078 -
Prospective Outcomes After Reconstruction and Radiotherapy for Breast Cancer
|
N/A | |
Recruiting |
NCT04174742 -
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
|
||
Completed |
NCT00064857 -
Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors
|
Phase 2 | |
Completed |
NCT03052166 -
Case Collection Study to Determine the Accuracy, Call Back and Cancer Detection Rates of QT Ultrasound in Breast Imaging
|